Revvity (RVTY) TD Cowen 46th Annual Health Care Conference summary

Key financial and operational highlights

• Q4 performance was strong across end markets and product execution, with notable growth in reproductive health, newborn screening, and ex-China immunodiagnostics; China outperformed expectations despite pressure.

• Cost measures initiated in late 2025 are expected to drive significant margin expansion in the second half of 2026, with continued benefits into the first half of 2027.

• Organic growth guidance for 2026 is 2%-3%, assuming stable pharma biotech markets; upside depends on further improvement in pharma biotech and preclinical spending.

• Life Science Solutions saw positive reagent growth in most recent quarters, while platform sales began recovering in Q4, expected to drive further reagent pull-through.

• Immunodiagnostics growth in the U.S. has been strong, with U.S. revenue share rising from 5% to 20% and a target to double, driven by autoimmune testing and expanded panels.

Market environment and segment outlook

• Pharma biotech markets are stabilizing, with increased funding and M&A activity signaling a shift from cost-cutting to growth and investment.

• High-content screening instruments are rebounding, while in vivo imaging remains reliant on academic funding and is slower to recover.

• China diagnostics is expected to decline further, with guidance reflecting a conservative stance due to policy uncertainties.

• Reproductive health and newborn screening continue to outperform, supported by geographic expansion and new disorder approvals.

• Partnership with Sanofi on type 1 diabetes screening is seen as a greenfield opportunity, with potential for broader adoption in coming years.

Software and innovation strategy

• Signals software suite is positioned as a net beneficiary of AI, with Synthetica launching in mid-2026 and a full rollout by early 2027; BioDesign fills a key portfolio gap.

• Signals business aims to double revenue in five years, with Synthetica and BioDesign as major growth drivers.

• User groups and customer feedback drive product development, with three major launches planned for the year.